GlassScriptPhysician profile
Natalie Dishman
NPI 1225036833
$16,798.25
in general payments reported to CMS, 2019-2025
62 companies · $2,526 in 2025
The $2,526 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,622 · 2020: $1,750 · 2021: $2,624 · 2022: $2,508 · 2023: $2,358 · 2024: $2,411 · 2025: $2,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,149 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,149.48 |
| Education | $145.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,904.29 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,577.27 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,294.38 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $991.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $986.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $761.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $701.28 | 2019-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $641.49 | 2019-2024 | Xarelto |
| Amgen INC. | $534.64 | 2019-2025 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $512.03 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.84 | 2019-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $459.04 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $452.15 | 2019-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $415.62 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $380.04 | 2019-2023 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.80 | 2019-2024 | Xifaxan, Trulance |
| Allergan, INC. | $334.86 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $305.42 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $280.23 | 2020-2023 | Linzess |
| Axsome Therapeutics, INC. | $277.27 | 2024-2025 | Auvelity |
| Amarin Pharma, INC. | $258.11 | 2019-2022 | |
| Abbott Laboratories | $251.73 | 2021-2023 | Freestyle Libre |
| Otsuka America Pharmaceutical, INC. | $204.25 | 2023-2025 | Rexulti, Nuedexta |
| Mylan Specialty L.P. | $199.92 | 2019-2024 | Yupelri |
| Corium, LLC | $190.51 | 2022-2025 | Azstarys |
| Eisai INC. | $176.21 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $154.09 | 2019-2022 | |
| Lundbeck LLC | $134.78 | 2023-2025 | Rexulti, Vyepti |
| Sumitomo Pharma America, INC. | $119.22 | 2024-2025 | Gemtesa |
| Biogen, INC. | $118.50 | 2020-2022 | |
| Tolmar, INC. | $102.48 | 2023-2025 | Jatenzo |
| Dexcom, INC. | $98.31 | 2024-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $91.01 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $86.41 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $80.92 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $71.92 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.39 | 2022 | |
| Esperion Therapeutics, INC. | $51.84 | 2020-2024 | Nexletol |
| Urovant Sciences INC | $51.44 | 2021-2022 | |
| Exact Sciences Corporation | $50.23 | 2025 | The Cologuard Plus Collection Kit |
| Ardelyx, INC. | $42.38 | 2024-2025 | Ibsrela |
| Inspire Medical Systems, INC. | $42.15 | 2025 | Inspire |
| Verona Pharma, INC. | $41.29 | 2025 | Ohtuvayre |
| Smith+Nephew, INC. | $41.23 | 2019-2020 | |
| Seqirus USA INC | $36.74 | 2024 | Fluad, Flucelvax |
| Xeris Pharmaceuticals, INC. | $35.53 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $34.36 | 2021 | |
| Neurocrine Biosciences, INC. | $32.93 | 2022-2023 | Ingrezza |
| Sanofi Pasteur INC. | $27.50 | 2025 | |
| Halozyme INC | $23.79 | 2023 | |
| Antares Pharma, INC. | $22.99 | 2024 | Xyosted |
| Vapotherm INC | $21.14 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $20.62 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.61 | 2023 | Onpattro |
| Hikma Pharmaceuticals USA | $18.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.96 | 2024 | Camzyos |
| Shire North American Group INC | $17.61 | 2019 | |
| Boston Scientific Corporation | $17.36 | 2023 | Watchman Access System |
| Gilead Sciences, INC. | $17.33 | 2021 | |
| Azurity Pharmaceuticals, INC. | $15.76 | 2024 | Horizant |
| Supernus Pharmaceuticals, INC. | $15.28 | 2019 | Xyosted |
| Corcept Therapeutics | $14.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Dishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.